Traditionally, insulin therapy has been considered the gold standard for management because of its efficacy in achieving tight glucose control and the fact that it does not cross the placenta. Insulin ...
MONDAY, July 28, 2025 (HealthDay News) -- For individuals with type 2 diabetes (T2D) and moderate cardiovascular risk treated with metformin, the risk for major adverse cardiovascular events is ...
MedPage Today on MSN
Cardiovascular Risks Resurface Old Concerns About Sulfonylureas for T2D
Sulfonylureas were flagged for excess cardiovascular risk when used for additional glucose lowering in type 2 diabetes (T2D) in an observational comparative effectiveness study. As second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback